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Introduction
Transforming growth factor beta (TGF-β) is the prototype
of a large family of signaling molecules with more than
40 members. TGF-β signals through the type I receptor
(TβRI) and the type II receptor (TβRII), and the Smad tran-
scriptional regulators, as well as many other signaling
pathways [1]. TGF-β plays an essential role in a wide array
of cellular processes, including early embryonic develop-
ment, cell growth, differentiation, motility, and apoptosis. In
nontransformed epithelial cells, the most studied TGF-β
response is growth inhibition. In some cell types, TGF-β
induces an epithelial to mesenchymal transition (EMT).
TGF-β plays an important, albeit complex, role in tumori-
genesis. In many tumors of epithelial origin, cells become
resistant to TGF-β-mediated growth inhibition. In parallel,
TGF-β induces EMT in tumor cells, and increases tumor
BSA = bovine serum albumin; Cdk = cyclin-dependent kinase; Cy = cyanine; EMT = epithelial to mesenchymal transition; IKKi = inducible IkB
kinase; IQGAP1 = IQ motif-containing the GTPase-activating protein 1; NF = nuclear factor; NIA = National Institutes of Aging; PCR = polymerase
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Abstract
Background Transforming growth factor beta (TGF-β) plays an
essential role in a wide array of cellular processes. The most
well studied TGF-β response in normal epithelial cells is growth
inhibition. In some cell types, TGF-β induces an epithelial to
mesenchymal transition (EMT). NMuMG is a nontransformed
mouse mammary gland epithelial cell line that exhibits both a
growth inhibitory response and an EMT response to TGF-β,
rendering NMuMG cells a good model system for studying
these TGF-β effects.
Method A National Institutes of Aging mouse 15,000 cDNA
microarray was used to profile the gene expression of NMuMG
cells treated with TGF-β1 for 1, 6, or 24 hours. Data analyses
were performed using GenePixPro and GeneSpring software.
Selected microarray results were verified by northern analyses.
Results Of the 15,000 genes examined by microarray, 939
were upregulated or downregulated by TGF-β. This represents
approximately 10% of the genes examined, minus redundancy.
Seven genes previously not known to be regulated by TGF-β at
the transcriptional level (Akt and RhoB) or not at all (IQGAP1,
mCalpain, actinin α3, Ikki, PP2A-PR53), were identified and
their regulation by TGF-β verified by northern blotting. Cell
cycle pathway examination demonstrated downregulation of
cyclin D2, c-myc, Id2, p107, E2F5, cyclin A, cyclin B, and cyclin
H. Examination of cell adhesion-related genes revealed
upregulation of c-Jun, α-actinin, actin, myosin light chain,
p120cas catenin (Catns), α-integrin, integrin β5, fibronectin,
IQGAP1, and mCalpain.
Conclusion Using a cDNA microarray to examine TGF-β-
regulated gene expression in NMuMG cells, we have shown
regulation of multiple genes that play important roles in cell
cycle control and EMT. In addition, we have identified several
novel TGF-β-regulated genes that may mediate previously
unknown TGF-β functions.
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invasion and metastasis [2]. NMuMG is a nontransformed
mouse mammary epithelial cell line that exhibits both a
growth inhibitory and EMT response to TGF-β [3]. These
properties render NMuMG cells a suitable model system
for studying these TGF-β actions.
Previous gene expression profiling studies of TGF-β action
on cell lines utilized cDNA microarrays to characterize
extracellular matrix-related genes in human dermal fibro-
blasts. The upregulation of these genes by TGF-β was
Smad mediated [4]. Another study examining the genetic
programs of epithelial cell plasticity directed by TGF-β uti-
lized the human keratinocyte HaCaT cell line [5]. In this
study, HaCaT cells were treated for up to 4 hours, and
microarray gene expression profiling was performed using
an array of 16,580 human cDNAs. The expression of 728
known genes (10% of those analyzed) was regulated by
TGF-β within 4 hours of treatment.
In the present study, we examined TGF-β regulation of
gene expression in the NMuMG epithelial cell line.
NMuMG cells were chosen as a model system because
the results are more relevant to our studies employing
transgenic mouse mammary tumor models, and because
NMuMG cells are a well-established model system for
studying both growth inhibition and EMT induced by
TGF-β [3]. EMT represents a complex physiological
process that includes dissolution of adherens junctions, a
change to spindle-like cell morphology, cytoskeletal re-
organization, increased cell motility, loss of epithelial
markers, and induction of mesenchymal markers. EMT
thus includes several cellular responses that may occur
through different mechanisms and at different time points
after TGF-β treatment. We consequently examined
changes in gene expression at 1, 6, and 24 hours after
TGF-β treatment.
In agreement with previous studies with HaCaT cells [5],
approximately 10% of the genes examined were regulated
by TGF-β in our microarray studies that queried more than
15,000 mouse cDNAs. Our study demonstrates that by 1
hour, TGF-β suppresses the expression of multiple genes
that play key roles in regulating cell cycle progression. At 6
and 24 hours, TGF-β enhances the expression of multiple
genes involved in regulating cell shape and cell adhesion,
and therefore may mediate TGF-β-induced EMT. Addition-
ally, several novel TGF-β-regulated genes were identified
that may play important roles in TGF-β responses.
Materials and methods
Cell culture and treatment
NMuMG cells were cultured in Dulbecco’s modified
Eagle’s medium containing 10% serum and 10µg/ml
insulin, until reaching 70–80% confluency. The cells were
treated with 4ng/ml TGF-β1 for 1, 6 or 24 hours.
Untreated cells were used as reference samples at each
time point, and were referred to as controls in the analy-
ses. Four independent replicates of each experiment were
performed. Cell morphology was examined under phase
contrast using an Olympus CK40 microscope (Melville,
NY, USA).
Growth inhibition assay
3H-thymidine incorporation assays were performed using
cells that had been treated for 24 hours with TGF-β. The
cells were pulsed with 3H-thymidine for the final 2 hours of
the treatment period. 3H-thymidine incorporation was
quantitated using a LS 6500 Multi-Purpose Scintillation
Counter (Beckman). Four replicates of each experiment
were performed, and each 3H-thymidine incorporation
experiment was performed in triplicate.
RNA sample preparation
NMuMG cells were lysed and homogenized in Trizol
reagent (Invitrogen, Carlsbad, CA, USA), and total RNA
was prepared according to the manufacturer’s instruc-
tions. Two rounds of extraction were performed to isolate
pure, high-quality total RNA. Thirty micrograms of total
RNA from each sample were used for reverse transcrip-
tion and cyanine (Cy)-dye incorporation.
cDNA microarray hybridization
The National Institutes of Aging (NIA) 15,000 cDNA
microarray was printed on three contiguous slides by the
Vanderbilt Microarray Shared Resource. The mouse 15,000
NIA microarray contains 15,247 genes of known and
unknown function, developed at the NIA. Detailed descrip-
tions of the gene array list, microarray hardware and proce-
dures are available online (http://array.mc.vanderbilt.edu).
The reference RNA samples from nontreated NMuMG
cells were labeled with Cy5, and the test RNA samples
from NMuMG cells treated with 4ng/ml TGF-β for 1, 6,
and 24 hours were labeled with Cy3. The Cy3-labeled and
Cy5-labeled samples were hybridized simultaneously to
the same array. Four independent replicates of TGF-β
treatment, RNA isolation and labeling, and microarray
hybridization were performed. To estimate ‘system noise’
that may be due to differences in Cy-dye labeling between
samples, we performed a ‘self-to-self’ hybridization, where
the same control sample was labeled separately with Cy3
and Cy5, and then hybridized.
Oligo dT for reverse transcription was synthesized by Invit-
rogen. SuperScript II reverse transcriptase (Invitrogen)
was used. A Qiagen PCR purification kit was used for
purification of probes (Qiagen, Valencia, CA, USA). Slides
were prehybridized to eliminate nonspecific interactions in
prehybridization solution: 1% BSA, 5×sodium chloride/
sodium citrate buffer (SSC), 0.1% SDS at 65°C for
45 min. Hybridizations were performed at 65°C for
14–16 hours in a humidified hybridization chamberR189
(Corning, Acton, MA, USA). After hybridization, the slides
were washed once each in solutions 1–3 (wash solution
1, 2×SSC, 0.1% SDS; wash solution 2, 1×SSC; wash
solution 3, 0.1×SSC) for 5 min at 55°C with gentle stir-
ring/agitation. Washed slides were centrifuged in a
conical tube for 5 min at 1600rpm to dry them. Microarray
slides were scanned using a Genepix 4000 B scanner
(Axon Instruments, Union City, CA, USA) at a resolution of
10µm, and the original data files were generated by
GenePixPro software (version 4.0; Axon Instruments).
Data analysis
A merged 15,000 data file was constructed by combining
the three original 5000 data files generated from the three
contiguous slides on which the total 15,000 gene clones
were printed. The GenBank accession number and the full
annotation gene name for each gene were incorporated.
Data analyses were performed using the GeneSpring
4.1.5 software package (Silicon Genetics, Redwood City,
CA, USA).
The normalization for the two-color cDNA microarray data
was designed as follows. The net signal intensity in each
channel (Cy3 or Cy5) was determined by subtracting the
local background from signal intensity values. Each gene’s
measured intensity was divided by its control channel
value (the reference RNA sample channel of Cy5). A
Cy3/Cy5 ratio represents the relative abundance of a
target transcript in TGF-β-treated and nontreated samples
respectively. When the control channel value was below
1000.0, the data point was considered too weak and was
discarded. Each sample was normalized to the 50th per-
centile of all measurements. The bottom 10th percentile
was considered background, and was subtracted from all
the other values.
Each experimental result was interpreted as the average of
the four replicates of each time point. Time-course gene
expression profiles were required to be present in two of
the four datasets, and to be present in at least two of the
three time points. A signal to control channel ratio >2.5
and a probability t test P<0.05 was defined as upregula-
tion by TGF-β. A signal to control channel ratio <0.4 and a
probability t test P<0.05 was defined as downregulation.
The annotated gene lists were constructed from all genes
represented in the normalized dataset. The differentially
expressed genes were classified into functional sub-
groups using Simplified Ontology in GeneSpring. For
each pathway, pathway images were saved as GIF files
and loaded into GeneSpring. Each pathway element was
identified in the normalized data.
Northern hybridization
All cDNAs of the NIA mouse 15,000 microarray were cloned
into the NotI/SalI sites of the ampicillin-resistant pSPORT1
vector (Invitrogen). The insert sizes ranged from 0.5 to 3kb,
with an average insert size of 1.5kb. The Escherichia coli
host strain used was DH10B. Plasmid DNA was isolated
using the High Pure Plasmid Isolation Kit (Roche, Indianapolis,
IN, USA). The inserts were verified for their correct annota-
tion by DNA sequencing. The reverse pSPORT1 primer was
used as the sequencing primer. To prepare cDNA probes,
cDNA inserts were amplified using pSPORT1 primers:
forward, GTTTTCCCAGTCACGACGTTG; reverse, TGA-
GCGGATAACAATTTCACACAG.
Plasmid DNA was used as the template for PCR amplifica-
tion under the following conditions: initial denaturation at
95°C for 1 min; then 40 cycles of denaturation at 94°C for
30s, annealing at 54°C for 30s, and extension at 72°C for
3.5 min. A final extension was performed at 72°C for
7 min. To examine the quality and quantity of PCR prod-
ucts, they were separated on 1.2% agarose gels. Specific
cDNA bands were recovered from the gels using QIAEX II
Gel Extraction Kits (Qiagen). Seventy-five nanograms of
cDNA was labeled with 32P using a Random Primed DNA
Labeling Kit (Roche).
For northern blot analysis, 10µg total RNA was separated
by electrophoresis on a 1% agarose, 0.66M formaldehyde
gel and transferred to Hybrid Nylon transfer membranes
(Amersham Biosciences, Piscataway, NJ, USA). After
transfer, the membrane was UV cross-linked (Stratalinker;
Stratagene, La Jolla, CA, USA). All cDNA probes were
hybridized overnight at 42°C in ULTRAhyb solution
(Ambion, Austin, TX, USA). Each filter was washed twice
for 5 min in 2×SSC and 0.1% SDS at 42°C, followed by
two 15 min washes each in 0.5×SSC and 0.1% SDS at
42°C, followed by two 15 min washes in 0.1×SSC, 0.1%
SDS at 42°C. Equal loading of gel lanes was confirmed by
hybridization with the house keeping gene 1B15. Results
were visualized and quantitated using a FUJIFILM-FLA-
5000 Phosphoimager (Fuji Photo Film Co. Ltd, Stamford,
CT, USA).
Results
Biological and gene expression responses of NMuMG
cells to TGF-β β
NMuMG cells react to TGF-β treatment with both an EMT
response and a growth inhibitory response (Fig.1). These
characteristics render NMuMG cells an appropriate model
system to study the signaling pathways mediating these
TGF-β effects. To examine TGF-β regulation of genes
involved in EMT and cell cycle control, we treated
NMuMG cells with TGF-β for 1, 6, or 24 hours, isolated
the total RNA, and performed gene expression profiling by
cDNA microarray. The relative transcript abundance was
expressed as Cy3/Cy5 ratios of signal intensities after
background subtraction in each channel. Data analysis
and quality control procedures are described in detail in
Materials and methods. TGF-β treatment resulted in the
upregulation or downregulation of 939 genes out of the
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Figure 1
Biological responses of NMuMG cells to transforming growth factor beta (TGF-β) treatment. (A) NMuMG cells were treated for 24 hours with
4 ng/ml TGF-β1 or left untreated (control), and were examined by phase-contrast microscopy. TGF-β1-treated cells exhibited an epithelial to
mesenchymal transition. (B) NMuMG cells were treated for 24 hours with 4 ng/ml TGF-β1 or left untreated (control). The cells were pulsed with
3H-thymidine for the final 2 hours of the treatment period. CPM, counts per minute.
Figure 2
Time course of transforming growth factor beta (TGF-β)1-dependent changes in gene expression. The Cy3 signal is shown on the y axis and the
Cy5 signal is shown on the × axis. The 0 hours graph represents the self–self hybridization for Cy-dye labeling noise control, and demonstrates a
minimal level of systemic noise. TGF-β induces a progressively larger alteration of gene expression over time.15,247 genes examined. Subtracting redundancy or
signals too weak to score, this represents approximately
10% of the genes analyzed.
The time course of TGF-β1-dependent changes in gene
expression demonstrates a progressively greater alteration
of gene expression over time (Fig.2). In general, TGF-β1
regulation of cell cycle-related genes occurred with an
onset of less than 1 hour, while TGF-β1 regulation of EMT-
related genes occurred with a later onset, with changes
first becoming apparent at 6 or 24 hours (see later).
Figure 3 and Table 1 present the distribution of downregu-
lated genes and of upregulated genes, and the sum of
upregulated and downregulated genes at each time point.
The total number of differentially expressed genes at each
time point does not differ significantly. The 6 and 24 hour
time points shared more TGF-β1-regulated genes than
were shared between the 1 and 6 hour time points, or the
1 and 24 hour time points. Full lists of TGF-β-regulated
genes at each time point can be accessed on our website
(http://array.mc.vanderbilt.edu/supl/tgfb_mouse).
Functional class distribution of the novel and known
TGF-β β1-regulated genes
Of the 939 genes regulated by TGF-β1, approximately
one-third (350 genes) can be classified into functional
groups. The classified genes were further separated into
two tables of genes previously reported or not previously
reported to be regulated by TGF-β. This was determined
by performing a Medline search using the gene name and
TGF-β as keywords. Tables of the complete dataset with
each gene in its functional category are presented on our
website (http://array.mc.vanderbilt.edu/supl/tgfb_mouse).
Tables 1 and 2 present some selected examples of known
or unknown TGF-β-regulated genes, respectively. The
genes involved in cell cycle regulation and cell adhesion
(see later) are included.
Northern analysis verification of microarray data
To validate the microarray results, we subjected nine of
the novel TGF-β-regulated genes to northern analysis. Of
the nine genes examined, seven exhibited TGF-β1-
induced changes in gene expression that matched those
observed in the microarray experiments. The seven novel
TGF-β1-regulated genes verified by northern analysis
include Akt, mCalpain, RhoB, PR53, actinin 3, Ikki (Fig.4)
and the IQ motif-containing GTPase-activating protein 1
(IQGAP1). IQGAP1 showed upregulation in NMuMG
cells after 1, 6 and 24 hours of treatment with TGF-β, sup-
porting the microarray data. As reported by other investi-
gators [6], we detected multiple IQGAP1 transcripts. The
IQGAP1 northern blot is thus not shown in Fig.4. Akt and




Venn diagrams demonstrating the distribution of downregulated genes, of upregulated genes, and of all regulated genes at each time point. The
expression of genes present within all three circles (white) is altered at all three time points. Genes present in two circles (purple, yellow and light
blue) are regulated at the two time points indicated. The expression of genes only present in one circle (red, green and blue) are only altered at one
time point. The number of differentially expressed genes at each time point does not differ significantly. The 6 and 24 hour time points shared more
transforming growth factor beta1-regulated genes than were shared between the 1 and 6 hour time points, or the 1 and 24 hour time points.at the translational level [7,8], but not at the transcriptional
level as we show here. Some of the TGF-β1-induced
changes in gene expression were also verified by real-time
RT-PCR (data not shown). In further support of the reliabil-
ity of the microarray experiments, genes that were repre-
sented multiple times in the array as different clones
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Table 1
Genes previously reported to be regulated by transforming growth factor beta (TGF-β β)
Response Response
Gene 1 hour 6 hours 24 hours Gene 1 hour 6 hours 24 hours
Cellular communication Cell cycle regulator
Platelet-derived growth factor No Up** Up*** CDK2 interacting protein (CINP) Down* No Down*
Fibroblast growth factor regulated Up** Up*** Up*** Cyclin D2 No Down* Down*
Cadherin 1 (Cdh1) No Down* No Cyclin D3 Up* No No
Signal transduction CDK9 Up* Up** Up*
Nfkb inducing kinase Up** No No Cdk4 Down* No No
RhoB Up*** Up*** Up** Cyclin A2 Down* No Down*
Serine/threonine kinase 25 No Up* No Cyclin B1 No No Down**
Integrin β4 No Up** No Cyclin B2 Down* No Down*
Bmp-1 No Up* Up* Cdc25a No Up* No
Janus kinase 2 (Jak2) No No Up* Cyclin H No No Down*
Integrin α3A No No Up* Cancer
Integrin β1 No Up* Up** c-myc Down** Down* No
Integrin-linked kinase (Ilk) No Up* Up* Akt Up** No No
Integrin β5 Up* Up** Up*** GRO1 oncogene Down** Down** Down**
Tyrosine phosphatase PTPT9 No Up* Up* Jun oncogene Up** No Up*
Ephrin-A1 (EFNA1) Up* No No E2 oncogene (Ets1) Up** Up** Up*
BMP-6 No Up* Up** Transport
TGF-β1-induced transcript  Up* Up** Up*** Glucose transport protein Up* No No
Colony stimulating factor 1 Up** Up** Up*** Ubiquitins and elongation factors
Intracellular components Elongation factor 2 (ef-2) No Up** Up**
TG interacting factor (Tgif) Up* Up** Up** Ubiquitin conjugating enzyme Up* Up* Up*
α-actinin No Up** Up** Enzyme
β-tropomyosin 2 No Up* Up*** Glutathione S-transferase Down* Down* Down*
Catenin src (Catns) No Up* Up* Protein tyrosine phosphatase Up* No No
Extracellular components Protease serine 15 (PRSS15) Up* Up* No
α1 type IV collagen  No No Up* Aldose reductase No Up** Up**
Fibronectin No Up* Up*** Disulfide isomerase (ERp59) No Up* No
Nucleic acid binding Casein kinase II (Csnk2a2) No Up* No
Helix–loop–helix DNA binding (Id) Up*** Down*** Down*** Ornithine decarboxylase No Up** Up**
Inhibitor of DNA binding (Idb3) No Down* Down* RNA polymerase II No No Up*
Translation initiation factor 2 No No Up* Bruton’s tyrosine kinase (Btk) No Up* Up*
Id2 No Down* Down* Cytochrome b-5 reductase (DIA1) No No Up*
The genes presented were upregulated (up) or downregulated (down) at least 2.5-fold (* 2.5-fold to fourfold, ** fourfold to sixfold, *** above sixfold)
and were found in a Medline search in which the gene name and TGF-β1 were used as keywords. The genes are grouped according to their
involvement in specific cellular functions.Available online http://breast-cancer-research.com/content/5/6/R187
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Table 2
Genes not previously reported to be regulated by transforming growth factor beta (TGF-β β)
Response Response
Gene 1 hour 6 hours 24 hours Gene 1 hour 6 hours 24 hours
Cellular communication Cell cycle regulator
Gadd45g Up*** Up* Up* Calcyclin binding protein Up* No Up*
(CACYBP)
cdc2 No Up* Up* E2F transcription factor 5 (E2f5) Down* Down* Down*
Hsp84-1 No Up* Up* Cancer
Junctional adhesion molecule No Up* Up* Suppression of tumorigenicity 13 No Up* Up*
(Jam)
Catenin α1 (Catna1) No Up* Up* Candidate tumor suppressor No Up* Up*
p33 ING1
Signal transduction Transport
NFKBIL2 gene for IκBR No Down*** Down** Solute carrier family 4 Up** Up** Up*
GTPase-activating protein GIT1 Up* Up* No ATPase, H+ transporting (ATP6J) No Up* Up*
Ras-GTPase-activating Up** No Up* Ca2+/calmodulin-dependent Up* Up*** Up**
SH3 binding kinase I
Ikki Down* Down* Down* Microtubular dynamics
Iqgap1 Up* Up** Up** Kinesin light chain 1 (Klc1) Up* No Up*
Milk fat globule-EGF factor No Up* Up** Microtubule-associated protein 4 Up** Up** Up**
8 protein
Tnfrh1 gene Up* No Up* Ubiquitin and elongation factors
Intracellular components Ubiquitin-specific protease 5 (Usp5) Up** Up* Up*
Actinin α3 (Actn3) Up* Up** Up* Elongation factor 1-alpha (EF 1-α) No Up** Up***
Actin-related protein 2/3 complex Up* Up* Up* Chaperone
Unconventional myosin-15 gene Up* No Up** Ccth gene for chaperonin Up* Up* Up**
Nonmuscle tropomyosin 5 No Up* Up* Chaperonin subunit 7 (Cct7) Up* Up* Up**
Melanoma X-actin (Actx) No Up* Up** Enzyme
Tropomyosin isoform 2 No Up* Up** Phosphoserine aminotransferase No Down** Down**
Actin-related protein 1  No Up* Up** α-methylacyl coenzyme (Macr1) No Down** Down**
Karyopherin β3 (KPNB3) No No Up* PLC-L2 for phospholipase C-L2 No Down** Down**
β-tropomyosin 2 No Up* Up*** Fatty acid coenzyme A ligase No Down** Down**
(FACL4)
TM-4 gene for fibroblast No Up** Up** Phospholipase A2, group 4 No No Up*
tropomyosin 4 (Pla2g4)
Calpain No Up** Up** Serine/threonine kinase (Unc51.1) No Up* Up**
Myosin light chain 2 (Mlc2) No Up* No Proteasome (Psmd13) Up** Up* Up*
Extracellular components Na,K-ATPase α-1 No Up** Up*
Cis-Golgi matrix protein GM130 Up** No Up* Aldehyde dehydrogenase 5 Up* Up* No
(ALDH5)
α-1(XVIII) collagen (COL18A1) No Up* Up** Protein phosphatase 2A (PR 53) Up* No Up*
Smarce1 No Up* Up* Casein kinase 1 (Csnk1e) Up* Up* Up***
Nucleic acid binding Serine/threonine phosphatase-2C Up* No No
HNRPM Up* Up* No Coatomer protein (Copg1) Up* Up* Up*
Hnrpu No Up* Up* MAP kinase kinase 3b Up** No No
Hnrnpc Up* Up* Up* Protein phosphatase 1 (Ppp1cc) No Up* No
Damage-specific DNA binding Up* Up** Up*** Na,K-ATPase β-subunit No Up** Up*
(Ddb1)
The genes presented were upregulated (up) or downregulated (down) at least 2.5-fold (*2.5-fold to fourfold, ** fourfold to sixfold, *** above sixfold)
and were not found in a Medline search in which the gene name and TGF-β1 were used as keywords. The genes are grouped according to their
involvement in specific cellular functions.exhibited identical expression profiles (examples can be
found in the supplementary tables at our website:
http://array.mc.vanderbilt.edu/supl/tgfb_mouse). In addi-
tion, our expression profiling results are consistent with
previously reported expression patterns of TGF-β1-
responsive genes [1,5].
Examination of cell cycle control and cell adhesion-
related genes by microarray
There are multiple ways to explore the biological signifi-
cance of results obtained in microarray experiments. One
may organize the genes into functional groups or signaling
pathways to examine the regulation of clusters of genes.
We were interested in identifying TGF-β-regulated genes
involved in the induction of EMT and cell cycle arrest. In
our study in NMuMG cells, the expression of many cell
cycle regulators was altered by TGF-β. One hour after
TGF-β treatment, cyclin D2, cdk4, E2F5, cyclin A, and
c-myc were downregulated. Six hours after TGF-β treat-
ment, cyclin D2, p107, E2F5, c-myc, and Id2 were down-
regulated. Twenty-four hours after TGF-β treatment,
cyclin D2, p107, E2F5, cyclin A, cyclin B, cyclin H, and Id2
were downregulated (Fig.5). These data are consistent
with these genes serving as mediators of TGF-β-induced
growth arrest.
The microarray results also revealed upregulation of a
number of genes that play a role in cell–cell and cell–matrix
adhesion and EMT. At 1 hour, c-Jun, β-integrin, and IQGAP
were upregulated. At 6 hours, actin, calpain, β-integrin,
fibronectin, collagen, myosin light chain, α-actinin,
β-catenin and IQGAP were upregulated. At 24 hours,
c-Jun, actin, calpain, α-integrin, β-integrin, fibronectin, colla-
gen,  α-actinin,  β-catenin and IQGAP were upregulated.
The only gene in this category observed to be downregu-
lated was E-cadherin at 6 hours (Fig.6). The results are
consistent with these genes playing a role in TGF-β1-medi-
ated changes in cell–cell and cell–substratum adhesion.
Our results are consistent with previous studies, but we
identified several novel TGF-β-regulated genes that could
play important roles in both EMT and cell cycle regulation,
including RhoB, mCalpain, actinin 3, IQGAP1, Ikki and
protein phosphatase 2A (PP2A)-PR53.
Discussion
The mechanisms by which TGF-β signals are not fully
understood. In this regard, gene expression profiling has
been used successfully by a variety of investigators to
explore genetic events involved in TGF-β signaling. Zavadil
and colleagues detected genetic programs of epithelial
cell plasticity directed by TGF-β [5]. Verrecchia and col-
leagues identified novel TGF-β/Smad gene targets in
dermal fibroblasts [4]. Chen and colleagues found defec-
tive repression of c-myc in breast cancer cells, suggesting
that this event is at the core of the TGF-β growth arrest
program [9]. Shen and colleagues discovered that the
activity of the guanine exchange factor NET1 is essential
for TGF-β-mediated stress fiber formation [10].
In the present study, we have selected the NMuMG non-
transformed mouse mammary gland epithelial cell line as a
model system to identify TGF-β-regulated target genes
involved in the control of growth inhibition and EMT. To
identify TGF-β-regulated genes, we employed a cDNA
microarray that represents 15,247 genes of known and
unknown function. We found that the expression of 939 of
the genes was altered by TGF-β regulation. This repre-
sents about 10% of the genes examined. Many of the
genes identified were previously determined to mediate
key biological responses to TGF-β. In addition, several
novel TGF-β-regulated genes were identified. The present
report provides a comprehensive view of the coordinated
regulation of genetic programs induced by TGF-β during
Breast Cancer Research    Vol 5 No 6 Xie et al.
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Figure 4
Verification of transforming growth factor beta (TGF-β)1-regulated
genes identified in microarray experiments by northern blotting. Ten
micrograms of total RNA were loaded in each lane. The resulting blots
were hybridized with cDNA probes specific for Akt, RhoB, PR53,
calpain, actinin, Ikki, or the house-keeping gene 1B15 as a loading
control. The figure shows mRNA expression in NMuMG cells after no
treatment (C) or after treatment with 4 ng/ml TGF-β1 for 1, 6, or
24 hours. The gene name and results from microarray data are shown
to the right of each blot. up, Upregulated; down, downregulated.the processes of cell cycle arrest and EMT. A remarkably
large number of genes undergo rapid changes in expres-
sion after TGF-β treatment. This report adds to the data-
base of hundreds of genes that are regulated by TGF-β
[5]. In addition, we have identified several novel TGF-β-
regulated genes, and have verified these results in north-
ern blotting experiments.
Table 1 presents previously identified TGF-β-regulated
genes, many of which are known to play important roles in
TGF-β induction of EMT and cell cycle arrest. Briefly, in
the cellular communication category, platelet-derived
growth factor was upregulated by TGF-β. Multiple genes
involved in cell adhesion were upregulated by TGF-β,
including integrins (integrin α3A, integrin β, integrin β5),
integrin-linked kinase, and the integrin ligand fibronectin.
These results are consistent with TGF-β activating inte-
grin-dependent cell adhesion. TGF-β upregulation of
α-actinin, β-tropomyosin 2, and p120 catenin may play a
role in the induction of EMT. RhoB was upregulated at 6
and 24 hours. RhoB is an endosomal small GTPase, and it
functions as a negative regulator of integrin and growth
factor signals [11]. Our previous results [8] and those of
other workers [12] suggest a novel mechanism of tumor
suppressive regulation by TGF-β, and implicate RhoB as a
negative regulator of TGF-β signal transduction.
TGF-β downregulation of the helix–loop–helix DNA
binding protein Id2 and of the inhibitor of DNA binding
Idb3 were previously identified as important events in
TGF-β-regulated signaling. These proteins belong to a
family of helix–loop–helix proteins that, in general, function
as positive regulators of cell growth and as negative regu-
lators of cell differentiation in many cell types [13].
TGF-β also regulates many genes involved in the progres-
sion of cancer. The proto-oncogene Akt is upregulated at
1 hour at the mRNA level. The Gro1 proto-oncogene is
downregulated by TGF-β at all the time points examined.
The roles that these gene products play downstream of
TGF-β during tumorigenesis have not been extensively
studied [14,15]. Well-established TGF-β responses such
as downregulation of c-myc and upregulation of the Jun
oncogene were also observed.
TGF-β is a potent growth inhibitor of epithelial cells.
TGF-β-mediated growth inhibition has been associated
with effects on G1 phase cyclins, cyclin-dependent
kinases (Cdks), Cdk-activating kinase, Cdc25A, and Cdk
inhibitors. TGF-β potently inhibits the activities of both the
cyclin D–Cdk4/Cdk6 and cyclin E–Cdk2 complexes,
resulting in the hypophosphorylation of pRbs and in the




Transforming growth factor beta (TGF-β)1 regulation of gene expression patterns of cell cycle elements. GeneSpring was used to search the
normalized 15,000 microarray data. A signal to control ratio above 2.5 was defined as upregulation (red). A signal to control ratio below 0.4 was
defined as downregulation (blue). Ratios between 0.4 and 2.5 were considered unregulated (black). Outlined genes were not represented in the
15,000 gene database.affect the expression levels of Cdk4, Cdk6, or Cdk2 in
exponentially proliferating cells. TGF-β decreases the
expression levels of cyclin A, which is probably the result
of cell cycle arrest in the late G1 phase. TGF-β has been
associated with upregulation of Cdk inhibitors p15Ink4B,
p21Cip1, and p27Kip1. The c-myc proto-oncogene has
been implicated in TGF-β-mediated growth inhibition.
TGF-β rapidly inhibits c-myc expression in a wide variety of
cell types [1]. c-Myc downregulation is a key event in the
TGF-β program of growth inhibition [9]. Additional mecha-
nisms mediating TGF-β-induced cell cycle arrest continue
to be uncovered. In our study, examination of cell cycle
genes demonstrated TGF-β1-induced downregulation of
cyclin D2, c-myc, Id2, p107, E2F5, cyclin A, cyclin B, and
cyclin H. These data are consistent with these genes
serving as mediators of TGF-β-induced growth arrest.
Of the genes that could be placed into functional cate-
gories, the expression of the majority of the genes was not
previously reported to be regulated by TGF-β. Table 2 pre-
sents some examples of genes that we have identified in
this study to be regulated by TGF-β that are involved in
cell signaling. Gadd45g was upregulated. Gadd45g
specifically interacts with the Cdk1–cyclin B1 complex,
resulting in inhibition of kinase activity [16]. The IQGAP1
gene is a target molecule of Cdc42 and Rac1. IQGAP
negatively regulates the E-cadherin–catenin complex-
based cell–cell adhesion by dissociating α-catenin and/or
β-catenin, a key molecule that links the
E-cadherin–catenin complex to the actin cytoskeleton.
These data suggest that TGF-β upregulation of IQGAP
may be one of the mechanisms by which TGF-β regulates
cell–cell adhesion [17]. Calpains are a family of Ca2+-
dependent intracellular cysteine proteases, including the
ubiquitously expressed micro-calpains and m-calpains.
Calpain activity may be regulated by targeting to specific
adhesion-related substrates [18].
Our results also demonstrate that TGF-β regulates multiple
genes involved in regulation of the actin cytoskeleton. Some
of these components include actinin α3, the Arp2–Arp3
complex, and myosin light chain 2. Four different isoforms of
tropomyosin were upregulated. Actinin α3 is a calcium-
dependent cytoskeletal protein with an actin-binding
domain. Actinin α3 is associated with adherens junctions
and desmosomes, together with E-cadherin, α-catenin,
β-catenin and γ-catenin, vinculin, α-actinin, and polymerized
actin. The genes α-actinin, myosin light chain 1/myosin light
chain 2, and tropomyosin are components of myofilaments
involved in cell contractility and motility.
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Figure 6
Transforming growth factor beta (TGF-β)1 regulation of the expression of genes involved in cell adhesion. GeneSpring was used to search the
normalized 15,000 microarray data using the parameters described in Fig. 5. Cad, cadherin; Int, integrin.During our studies we identified several genes not previ-
ously reported to be regulated by TGF-β that are regu-
lated by TGF-β in NMuMG cells. These novel
TGF-β-regulated genes include IQGAP1, mCalpain and
actinin α3, which were discussed earlier, and also Ikki and
PP2A-PR53. For the first time, we show in the present
study that Ikki is downregulated by TGF-β within 1 hour of
treatment, and that downregulation persisted for at least
24 hours. NF-κB activation depends on the phosphoryla-
tion and degradation of its inhibitor protein, IkB. The phos-
phorylation of IkBα is initiated by an IkB kinase complex
that includes a catalytic heterodimer composed of IkB
kinase 1 (IKK-1) and IkB kinase 2 (IKK-2) [19]. A novel
inducible IkB kinase (IKKi) has recently been described.
IKKi is functionally and structurally distinct from the consti-
tutively expressed IKK-1 and IKK-2. In contrast to TGF-β,
tumor necrosis factor alpha stimulated IKKi expression, an
effect that persisted for at least 24 hours [20]. The biologi-
cal significance of TGF-β downregulation of IKKi is cur-
rently under investigation. PP2A is a multifunctional
serine/threonine phosphatase that is critical to many cellu-
lar processes, including cell cycle regulation and signal
transduction. PR53 belongs to one of the families of PP2A
regulatory subunits. The significance of TGF-β regulation
of PR53 expression is unknown [21].
Altogether, our results are consistent with the important
role of TGF-β in regulating focal adhesions, integrin-based
adhesion, actin cytoskeletal architecture, and cell motility.
TGF-β plays a profound role in the dedifferentiation of
epithelial cells, causing depolarization, disruption of
epithelial interactions, altered expression of extracellular
matrix proteins, rearrangement of the cytoskeleton, and
formation of actin stress fibers. These TGF-β responses
provide cells with increased metastatic potential and with
increased motility.
Over the past few years, tremendous progress has been
made in identifying signal transduction pathways activated
by TGF-β family members. In the present study, we have
combined microarray analysis with the examination of spe-
cific signaling pathways. Because of the important role
that TGF-β plays in controlling cell proliferation and cell
adhesion, we used the signaling elements involved in
these processes as a template for the analysis of our
microarray results. Many of the genes that we identified as
being regulated by TGF-β were previously reported to be
downstream targets of TGF-β. We also discovered several
novel TGF-β target genes known to play roles in regulating
cell adhesion, and thus EMT, and also cell cycle regula-
tion. Examining the biological functions of these novel
TGF-β target genes will increase our knowledge of the
mechanisms by which TGF-β mediates its cellular effects.
Furthermore, our results indicate several possible points of
convergence between TGF-β signaling and other major
intracellular and intercellular signaling systems.
Conclusion
A 15,247 cDNA microarray was used to examine TGF-β-
regulated gene expression in mouse mammary NMuMG
cells. Expression of 10% of the genes examined (939)
was altered by TGF-β treatment. We have reported a com-
prehensive analysis of the coordinated regulation of
genetic programs induced by TGF-β in mammary epithelial
cells during the processes of cell cycle arrest and EMT. In
addition, several genes previously not known to be regu-
lated by TGF-β at the transcriptional level were identified,
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